ATLAS News · Pharmaceuticals
The FDA says GLP-1 drugs carry a potential risk of NAION, a rare eye condition, and requires drugmakers to inform patients and doctors.
The FDA on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition sometimes called an "eye stroke" [3]. It required pharmaceutical companies to inform patients and doctors of the risk [3].
The FDA warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition and required pharma companies to inform patients and doctors [3]. Headlines from CNN and the Financial Times also report that the agency ordered new warnings, naming Ozempic and Zepbound in the CNN headline [1][2].
The condition is called non-arteritic anterior ischemic optic neuropathy, or NAION, and is caused by insufficient blood flow to the optic nerve [3]. It typically causes sudden vision loss and, in severe cases, can lead to blindness [3].
STAT reports there are currently no proven treatments for the condition [3]. It adds that side effects can show up in real-world use that were not observed in clinical trials [3].
Sector relationship, not a demonstrated effect: ATLAS has no evidence that this story moves these companies' share prices. They appear for their activity in the sector and are shown with ATLAS data.
Maker of Zepbound, subject to the FDA's new NAION eye risk warning requirement. · Healthcare
Maker of Ozempic, subject to the FDA's new NAION eye risk warning requirement. · Healthcare
ATLAS model estimates put Eli Lilly's fair value at $810.10, within a range of $663.02 to $1,034.88. Its November 9 close of $1,354.00 was 67.14% above that estimate. For Novo Nordisk, the estimate is $83.46 (range $70.75 to $106.94), and its November 9 close of $40.31 was 51.70% below it. These are model estimates, not promises.
This is a sector relationship, not a demonstrated effect: there is no evidence that this story moves these companies' share prices. Figures come from closing prices and may change.
Start in under a minute. Information, not advice.
There is no evidence of that. The companies appear because of their sector relationship, not a demonstrated effect.
Non-arteritic anterior ischemic optic neuropathy, a rare condition caused by insufficient blood flow to the optic nerve. It typically causes sudden vision loss [3].
It required pharma companies to inform patients and doctors of the potential risk [3].
Closing prices, fair value, probabilities, earnings and dividends: ATLAS own data as of November 9, 2026. How we calculate fair value.
Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy
ATLAS